Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Payables for 16 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • Quarterly Payables rose 154.17% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Jan 2026, up 154.17% year-over-year, with the annual reading at $399204.0 for FY2025, 94.32% down from the prior year.
  • Payables for Q1 2026 was $1.2 million at PharmaCyte Biotech, up from $1.1 million in the prior quarter.
  • The five-year high for Payables was $7.0 million in Q2 2024, with the low at $3015.0 in Q1 2022.
  • Average Payables over 5 years is $2.1 million, with a median of $861276.0 recorded in 2022.
  • The sharpest move saw Payables skyrocketed 14690.55% in 2023, then plummeted 94.32% in 2025.
  • Over 5 years, Payables stood at $861276.0 in 2022, then surged by 390.14% to $4.2 million in 2023, then dropped by 3.61% to $4.1 million in 2024, then plummeted by 74.03% to $1.1 million in 2025, then increased by 16.64% to $1.2 million in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $1.2 million, $1.1 million, and $465209.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.